JP2024535712A5 - - Google Patents

Info

Publication number
JP2024535712A5
JP2024535712A5 JP2024512988A JP2024512988A JP2024535712A5 JP 2024535712 A5 JP2024535712 A5 JP 2024535712A5 JP 2024512988 A JP2024512988 A JP 2024512988A JP 2024512988 A JP2024512988 A JP 2024512988A JP 2024535712 A5 JP2024535712 A5 JP 2024535712A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/057978 external-priority patent/WO2023026235A1/en
Publication of JP2024535712A publication Critical patent/JP2024535712A/ja
Publication of JP2024535712A5 publication Critical patent/JP2024535712A5/ja
Pending legal-status Critical Current

Links

JP2024512988A 2021-08-27 2022-08-25 抗psma抗体及びその使用 Pending JP2024535712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163237663P 2021-08-27 2021-08-27
US63/237,663 2021-08-27
PCT/IB2022/057978 WO2023026235A1 (en) 2021-08-27 2022-08-25 Anti-psma antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024535712A JP2024535712A (ja) 2024-10-02
JP2024535712A5 true JP2024535712A5 (cg-RX-API-DMAC7.html) 2025-09-02

Family

ID=85322846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512988A Pending JP2024535712A (ja) 2021-08-27 2022-08-25 抗psma抗体及びその使用

Country Status (15)

Country Link
US (2) US11987641B2 (cg-RX-API-DMAC7.html)
EP (1) EP4392454A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024535712A (cg-RX-API-DMAC7.html)
KR (1) KR20240049342A (cg-RX-API-DMAC7.html)
CN (1) CN118176213B (cg-RX-API-DMAC7.html)
AU (1) AU2022333321A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230346A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000565A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024002244A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000036A (cg-RX-API-DMAC7.html)
IL (1) IL311070A (cg-RX-API-DMAC7.html)
JO (1) JOP20240041A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002476A (cg-RX-API-DMAC7.html)
PE (1) PE20240727A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023026235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
WO2025183244A1 (ko) * 2024-02-29 2025-09-04 주식회사 피비앱셀 Psma에 대한 항체 및 그의 용도
WO2026162289A1 (en) * 2025-01-29 2026-08-06 Philogen S.P.A. High-affinity cross-reactive anti-psma antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
CN103221398B (zh) 2010-07-23 2016-03-23 特拉华大学 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应
BR112013027224A8 (pt) * 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
CA2880791A1 (en) 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
JP7366518B2 (ja) 2015-05-06 2023-10-23 ヤンセン バイオテツク,インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンiii型ドメイン
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP2019506155A (ja) * 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドCrescendo Biologics Limited 治療分子
SG11201810470XA (en) * 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
ES2992988T3 (en) 2017-03-30 2024-12-20 Univ Cornell Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
WO2020001344A1 (en) * 2018-06-29 2020-01-02 Beijing Biocytogen Co., Ltd ANTI-CD3e ANTIBODIES AND USES THEREOF
EP3830132B1 (en) * 2018-07-31 2022-11-23 Heidelberg Pharma Research GmbH Humanized antibodies against psma
CN109467602A (zh) * 2018-11-05 2019-03-15 暨南大学 与cxcr4结合的人源蛋白及其应用
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CA3136892A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof

Similar Documents

Publication Publication Date Title
ES2439802T3 (es) Anticuerpos tri- o tetraespecíficos
JP2025016349A5 (cg-RX-API-DMAC7.html)
JP2023528350A5 (cg-RX-API-DMAC7.html)
ES2537100T3 (es) Anticuerpos biespecíficos trivalentes
JP2024119791A5 (cg-RX-API-DMAC7.html)
CN102459345B (zh) 双特异性抗原结合蛋白
ES2442917T3 (es) Proteínas de unión a antígenos, tetravalentes y biespecíficas
US20150166670A1 (en) Multispecific antibodies
JP2020534351A5 (cg-RX-API-DMAC7.html)
JP2021534797A5 (cg-RX-API-DMAC7.html)
RU2007114328A (ru) Антитела к ох40l
WO2010112194A1 (en) Antigen-binding polypeptides and multispecific antibodies comprising them
CA2987118A1 (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
WO2010112193A1 (en) Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP2024532372A5 (cg-RX-API-DMAC7.html)
US20130245233A1 (en) Multispecific Molecules
JP2023522730A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
HK1218554A1 (zh) 人pac1抗體
CN111448217A (zh) 双特异性抗原结合构建体
CA3092610A1 (en) De-immunised anti-erbb3 antibodies
JP2024535705A5 (cg-RX-API-DMAC7.html)
JP2024534034A5 (cg-RX-API-DMAC7.html)
JP2024502863A5 (cg-RX-API-DMAC7.html)